There is strong clinical evidence that trastuzumab, a monoclonal antibody targeting the
human epidermal growth factor receptor (HER) two tyrosine kinase receptor, is an important …

The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or
amplified in∼ 15% of breast cancer patients and was identified a quarter century ago as a …

Therapeutic antibodies have shown great promise as targeted agents in the treatment of
patients with cancer. Trastuzumab, a humanized monoclonal antibody targeting human …

The advent of HER2-directed therapies has significantly improved the outlook for patients
with HER2-positive early stage breast cancer. However, a significant proportion of these …

Trastuzumab (Herceptin) is a therapeutic monoclonal antibody specific for the human
epidermal growth factor receptor type 2 (HER2), a cell-surface tyrosine kinase receptor …

The therapeutic strategy for breast cancer with the use of targeted drugs is, at present,
mainly focused on coping with HER2. Currently, lapatinib and trastuzumab are in …

The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural
history of early and metastatic HER2-overexpressing breast cancer. Many other agents …

It has been over 20 years since the discovery of the human epidermal growth factor receptor
2 (HER2), a tyrosine kinase receptor that is a potent oncoprotein in breast and other cancers …

Abstract Approximately 15–20% of all breast cancers are human epidermal growth factor
receptor 2 (HER2) positive, with clinical studies having validated the HER2 receptor tyrosine …

The outlook for patients with HER2-positive breast cancer was revolutionized by the
development of trastuzumab (Herceptin), a humanized murine monoclonal antibody. Use of …